Aug 13, 2020
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA
May 25, 2020
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)(1)
Apr 08, 2020
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME(TM) Technology
Apr 07, 2020
EmphyCorp N115 News: Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide
Mar 24, 2020
EmphyCorp News: As Reported in The Lancet - Clinical Features of Patients Infected with the 2019 novel Coronavirus in Wuhan, China
Mar 23, 2020
Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis
Mar 17, 2020
EmphyCorp News: Nitric Oxide is currently being tested in Clinical Trials as a Potential Treatment for Patients infected with the Coronavirus
Mar 09, 2020
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Mar 04, 2020
Pulmonary Fibrosis Foundation Launches Industry Consortium To Identify Biomarkers In Pulmonary Fibrosis
Mar 03, 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Mar 02, 2020
Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer
Feb 13, 2020
Promedior Announces Completion of Acquisition by Roche
Feb 06, 2020
PharmaNest Announces Kidney and Lung Fibrosis Quantification Data to Be Presented at the 2020 Fibrosis and Tissue Repair Keystone Symposium
Jan 14, 2020
Rx Globally Patented Non-Steroidal Nasal Spray for All Lung Diseases including Pulmonary Fibrosis, CF, COPD, Unmet Needs with No Known Side Effects that can also be used to Deliver Antivirals, Antimicrobials, Insulin, and other Drugs
Jan 08, 2020
Pliant Therapeutics Appoints Gayle Crowell to its Board of Directors
Dec 17, 2019
Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair
Nov 20, 2019
New Report Reveals Major Gaps in Quality of Care for Canadians with Rare Lung Disease
Nov 15, 2019
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
Nov 11, 2019
Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
Nov 07, 2019
New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting